dissemination – Page 59 – Communicable Diseases Research

Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-112022-10-29
Journal: Trials [Category] Coronavirus, SARS,

Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections

Review

Published on 2020-09-102022-10-28
Journal: Vaccines [Category] COVID-19,

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Ability Ability to walk Activation adhere administer ambulatory patient anatomical Anticoagulant treatment anticoagulation antiplatelet Atrial fibrillation baseline bleeding Blinding block size body temperature calculated Cardiovascular events characterized Chemotherapy clearance clinical benefit clinically Coagulation Coagulopathy Comorbidity Comparator group conducted contraindication control group coronary syndrome coronavirus cough COVID-19 creatinine criteria Critical current death defined diagnosed diagnosed with COVID-19 Diagnosis Disseminated intravascular coagulation dissemination dose Efficacy elderly element eligibility criteria eligible enoxaparin enrolment event event rate experimental group Face mask FIVE fixed heart failure help heparin-induced thrombocytopenia Hospitalization hospitals hygiene hypersensitivity impairment IMPROVE In-hospital Inflammation information injection inoperable Intervention intervention group invasive Ischemia Laboratory lack Last Liver disease lower limb major bleeding malignancy multicentre Myocardial number objective Older Open-label outcome parameter participant Participation Patient performed Platelet Positive test Presence prevention protocol provided Radiotherapy randomised randomised controlled trial randomization randomization ratio Randomized Randomized controlled trial receive reduce renal respiratory symptom resulting risk factor Sample size SARS-CoV2 secondary Seven Shortness of breath sore throat Spinal cord injury status Stratified randomization stroke Study protocol Support surgical survival symptomatic the patient therapy Thromboprophylaxis thrombosis total sample size Transport trauma Travel treated Treatment undergo university university hospital Venous Thromboembolism vessel viral disease VTE website
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter

Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 7-point ordinal scale absence addition administration Admission ALT anticipated assigned AST baseline biological parameters candidate Care clinical Clinical research clinical status clinical trial clinician Comorbidity conditions Control control arm control group Coronavirus infections Council COVID 19 COVID-19 COVID-19 infection criteria current D-dimer Day death rate decrease discharge dissemination dose drug Duration early stage Efficacy element ELISA enrolment EudraCT European evaluate exclusion criteria exploratory extracorporeal membrane oxygenation Frame harmonization hospitalisation hospitalised hospitalised patient hyperinflammatory status hypersensitivity Hypothesis identify IL-6 IL-6 levels IL-6 receptor inhibitors IL-6R In-hospital incidence Inclusion inclusion criteria independent Infection Informed inhibitor interstitial pneumonia Intervention intervention group intestinal perforation Invasive mechanical ventilation investigator investigator-initiated lactation Local marker measure mechanical ventilation moderate moderate-severe neutrophil count Non-invasive non-invasive ventilation number number of death objective Open label trial outbreak outcome oxygen Oxygenation pandemic participant pathogen patients treated performed Platelet Pneumonia positive positive RT-PCR Positive test Prednisone Presence Prevent progression protocol random randomisation randomised randomised controlled trial receive recruited recruitment Registered reported requiring supplemental oxygen responsible routine clinical practice RT-PCR SAEs Sample size sarilumab SARS-CoV-2 SARS-COV-2 infection score Sepsis Serious Adverse Event serum Severe COVID-19 Infection single center single dose Spain Standard Standard of care status Study protocol Subcutaneous subcutaneous injection the patient therapy treated Treatment treatment arm treatment with tocilizumab Trial ULN union unit verbal website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter

Combating SARS-CoV-2: leveraging microbicidal experiences with other emerging/re-emerging viruses

Microbiology

Published on 2020-09-082022-10-28
Journal: PeerJ [Category] COVID-19,

Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

COVID-19 질병으로 고통받는 중환자의 기계적 환기에 대한 항응고, The ANTI-CO 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-09-072022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Abnormalities Administered allergic Anti-Co trial Anticoagulant anticoagulation anticoagulation treatment approval aPTT assumed attending physicians bivalirudin blinded Blinding Clinical improvement Coagulation comparator control group Controlled trial Corporation COVID-19 COVID-19 disease Critically ill patient D-dimer D-dimers dissemination distress dose dropout drug element eligibility eligible exclusion criteria expected experimental group FiO2 for inclusion groups heparin ICU IMPROVE include Inclusion inclusion criteria intervention group intravenously Invasive mechanical ventilation limit Local mechanical ventilation normally distributed number objective on mechanical ventilation outcome P/F P/F ratio PaO2 paO2/fiO2 parallel group parameter participant Patient patients patients with COVID-19 performed Physicians positive power power of 80% Pregnancy Primary outcome protocol randomised randomised controlled trial randomization Randomized receive recruitment Registered registration number respiratory distress Respiratory failure Sample size sample size calculation screened standard treatment status study drug Study protocol subcutaneously subject Taking the mean the patient thrombosis title treated Treatment treatment group Trial registration website
[DOI] 10.1186/s13063-020-04689-1 PMC 바로가기 [Article Type] Letter

Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial

Letter

Published on 2020-09-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Acacia addition agent Anti-inflammatory Arabic assigned assistant baseline baseline value blind change Clinical guidelines clinical trial computer-generated conducted Control COVID COVID 19 COVID 19 patient COVID-19 COVID-19 patients CRP Cytokines Date death diagnosed dissemination Efficacy element eligible patient Factor Gender group groups Gum Gum Arabic Hospital admission IL10 IL6 IL8 immunomodulation immunomodulatory independent Intervention Local mortality rate number objective outcome parallel-group participant Patient patients PCR Pectin phase Placebo placebo-controlled clinical trial Potential Prospective protocol provided random randomised randomised controlled trial randomization Randomized Randomly Real-time PCR receive Research response role Sample size secondary sequence seropositive Soba standard care state status TNFα Treatment Trial Tumor Two-arm university Version Viral load website
[DOI] 10.1186/s13063-020-04707-2 PMC 바로가기 [Article Type] Letter

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Research Article

Published on 2020-09-032022-10-30
Journal: JCI Insight [Category] COVID-19, SARS,

[키워드] adaptive Adaptive immunity Administered Blood canonical COVID-19 COVID-19 infection COVID-19 infections COVID-19 patient COVID-19 patients Critically ill cytokine Cytokine storm diagnostic dissemination Elevation ELISPOT evaluate Ex vivo functional healthy control Host host immunity host response Hyperinflammatory hypothese Hypothesis IL-6 level IL-7 immune effector cell immune function immunoassay Immunosuppression immunosuppressive innate immune Innate immunity lack less monocyte mononuclear cell morbidity and mortality organ injury pathologic Patient patients patients with COVID-19 produced proinflammatory cytokines protective immunity reduced restored Sepsis stimulated Support suppresse T cell T cell subset Therapies TNF-α Volunteer
[DOI] 10.1172/jci.insight.140329 PMC 바로가기 [Article Type] Research Article

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hours absence Admission all-cause mortality Arm blinded chest imaging clinical commenced Confirmed COVID-19 criteria CRP D-dimer Data analysis database death defined demonstrated determine disease dissemination dose Efficacy element eligible participant enrolled EudraCT Evidence evidence of evidenced facilitate ferritin fibrinogen hospital humanized monoclonal antibody hyper-inflammation IL-6 IL6 immunology independent Infection inflammatory state infused inhibit interleukin-6 intravenous tocilizumab intubation investigators Ireland LDH low dose management Mater moderate to severe multicentre non-invasive ventilation number objective Older open label outcome PaO participant Patient patients with COVID-19 PCR-confirmed COVID-19 performed positive PCR Potential treatment primary endpoint Primary outcome progression protocol pulmonary randomisation randomised randomised controlled trial Randomised trial receive recruited reduced Registered reported Respiratory failure Respiratory function Sample size SARS-CoV2 infection single dose Stage stage 2 Standard Standard dose status Study protocol subject subjects subsequent systemic inflammation target temperature Therapeutics Tocilizumab treatment group Trial ULN university Ventilation website
[DOI] 10.1186/s13063-020-04680-w PMC 바로가기 [Article Type] Letter

Implementation Science to Respond to the COVID-19 Pandemic

Public Health

Published on 2020-09-022022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, MERS,